Your browser doesn't support javascript.
loading
Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL).
Gonzalez, Pedro Engel; Hlatky, Mark A; Manson, JoAnn E; Buring, Julie E; Lee, I-Min; Cook, Nancy R; Bubes, Vadim; Stone, Neil J.
Afiliação
  • Gonzalez PE; Feinberg School of Medicine, Northwestern University, Chicago, IL.
  • Hlatky MA; Stanford University School of Medicine, Stanford, CA. Electronic address: hlatky@stanford.edu.
  • Manson JE; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.
  • Buring JE; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.
  • Lee IM; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.
  • Cook NR; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.
  • Bubes V; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Stone NJ; Feinberg School of Medicine, Northwestern University, Chicago, IL.
Am Heart J ; 252: 39-41, 2022 10.
Article em En | MEDLINE | ID: mdl-35717999
ABSTRACT
Statins are highly effective medications that reduce risk of atherosclerotic cardiovascular disease, but are very commonly discontinued by patients because of muscle symptoms. The risk factors for statin-associated muscle symptoms (SAMS) are not well understood, so in this study we examined the predictors of SAMS in a well-studied cohort of patients in the VITAL trial. We found that female sex and younger age (50-64 years) were significant, independent predictors of higher rates of SAMS.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Graxos Ômega-3 / Inibidores de Hidroximetilglutaril-CoA Redutases Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Graxos Ômega-3 / Inibidores de Hidroximetilglutaril-CoA Redutases Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article